Literature DB >> 16198476

Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas.

Christian Mawrin1, Elmar Kirches, Sabine Diete, Falk R Wiedemann, Thomas Schneider, Raimund Firsching, Siegfried Kropf, Bernhard Bogerts, Christian K Vorwerk, Sabine Krüger, Knut Dietzmann.   

Abstract

The FGFR4 codon 388 polymorphism (Arg(388), Arg/Gly(388) or Gly(388)) was determined in glioblastoma multiforme (GBM), anaplastic astrocytomas (AA), diffuse astrocytomas (DA), and control muscles. Arg(388) was rare in AA, GBM, muscles, and was absent in DA. The Arg/Gly(388) and the Gly(388) frequency was equal among GBM and controls. FGFR4 expression was not related to codon 388 in GBM, and no survival differences between Arg/Gly(388) and Gly(388) tumors were found. U87 cells (Arg/Gly(388)) did not show higher invasion than U138 cells (Gly(388)). This suggests that the FGFR4 codon 388 status does not play a major role in malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198476     DOI: 10.1016/j.canlet.2005.08.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.

Authors:  Yan-Ying Shen; Ya-Chao Lu; Dan-Ping Shen; Yuan-Jie Liu; Xin-Ying Su; Guan-Shan Zhu; Xiao-Lu Yin; Xing-Zhi Ni
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

Review 2.  Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Authors:  Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.

Authors:  S Streit; D S Mestel; M Schmidt; A Ullrich; C Berking
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640

4.  Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.

Authors:  Si-Wei Xiong; Jianqun Ma; Fen Feng; Wen Fu; Shan-Rong Shu; Tianjiao Ma; Caixia Wu; Guo-Chang Liu; Jinhong Zhu
Journal:  Oncotarget       Date:  2017-04-11

5.  Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer.

Authors:  Tao Peng; Yangyang Sun; Zhiwei Lv; Ze Zhang; Quanxin Su; Hao Wu; Wei Zhang; Wei Yuan; Li Zuo; Li Shi; Li-Feng Zhang; Xiaoli Zhou; Yuanyuan Mi
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

6.  Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.

Authors:  Lisa Gabler; Carola Nadine Jaunecker; Sonja Katz; Sushilla van Schoonhoven; Bernhard Englinger; Christine Pirker; Thomas Mohr; Petra Vician; Mirjana Stojanovic; Valentin Woitzuck; Anna Laemmerer; Dominik Kirchhofer; Lisa Mayr; Mery LaFranca; Friedrich Erhart; Sarah Grissenberger; Andrea Wenninger-Weinzierl; Caterina Sturtzel; Barbara Kiesel; Alexandra Lang; Brigitte Marian; Bettina Grasl-Kraupp; Martin Distel; Julia Schüler; Johannes Gojo; Michael Grusch; Sabine Spiegl-Kreinecker; Daniel J Donoghue; Daniela Lötsch; Walter Berger
Journal:  Acta Neuropathol Commun       Date:  2022-04-28       Impact factor: 7.578

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.